Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Harvard University · Dana-Farber Cancer Institute · +8 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
714
total citations
- FWCI
- 35.05
- Percentile
- 100%
- References
- 29
Citations per year
Authors
9- IEIan E. KropCorresponding
Harvard University, Dana-Farber Cancer Institute
- SKSung‐Bae Kim
University of Ulsan, Asan Medical Center, Ulsan College
- AGAntonio González-Martı́n
MD Anderson Cancer Center Madrid
- PLPatricia LoRusso
Wayne State University, The Barbara Ann Karmanos Cancer Institute
- JFJean-Marc Ferrero
Centre Antoine Lacassagne
Topics & keywords
Topics
Keywords
- Medicine
- Trastuzumab emtansine
- Lapatinib
- Internal medicine
- Oncology
- Trastuzumab
- Interim analysis
- Population
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.